{"id":185469,"date":"2015-02-21T03:46:39","date_gmt":"2015-02-21T08:46:39","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/new-target-for-prostate-cancer-treatment-discovered.php"},"modified":"2015-02-21T03:46:39","modified_gmt":"2015-02-21T08:46:39","slug":"new-target-for-prostate-cancer-treatment-discovered","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/new-target-for-prostate-cancer-treatment-discovered.php","title":{"rendered":"New target for prostate cancer treatment discovered"},"content":{"rendered":"<p><p>  Keck Medicine of the University of Southern California (USC)  scientists have found a promising new therapeutic target for  prostate cancer. The findings offer evidence that a newly  discovered member of a family of cell surface proteins called  G-protein coupled receptors (GPCRs) promotes prostate cancer cell  growth. The protein, GPR158, was found while the researchers were  looking for new drug targets for glaucoma.<\/p>\n<p>    Prostate cancer is the second most common cancer in American    men, after skin cancer, according to the American Cancer    Society (ACS). The ACS projects more than 27,000 deaths from    prostate cancer in 2015 and is the second leading cause of    cancer death in American men, behind lung cancer. One man in    seven will be diagnosed with prostate cancer during his    lifetime.  <\/p>\n<p>    \"When a prostate cancer tumor is in its early stages, it    depends on hormones called androgens to grow,\" said Nitin    Patel, Ph.D., research scientist at the Institute for Genetic    Medicine at the Keck School of Medicine of USC, and    corresponding author on the research. \"Eventually it progresses    to a more lethal form, called castration-resistant prostate    cancer (CRPC), and is resistant to drugs that block androgen    receptors. We found that GPR158, unlike other members of the    GPCR family, is stimulated by androgens, which in turn    stimulates androgen receptor expression, leading to tumor    growth.\"  <\/p>\n<p>    The team also discovered that GPR158 is associated with    neuroendocrine transdifferentiation (NED) of epithelial    prostate tumor cells, which plays a critical role in    development of resistance to contemporary androgen    receptor-target therapies. The scientists found that prostate    cancer patients with elevated GPR158 expression experienced    recurrence of prostate cancer. The GPR158 protein is a likely    target for new prostate cancer drugs.  <\/p>\n<p>    The researchers used a conditional Pten knockout mouse model of    prostate cancer in collaboration with Keck School of Medicine    of USC researchers Mitchell Gross, Chun-Peng Liao and Pradip    Roy-Burman.  <\/p>\n<p>    The team is now exploring the molecular pathways involved in    the functional role of GPR158 in NED in the development of CRPC    and exploring GPR158-targeted antibody therapeutics.  <\/p>\n<p>    Story Source:  <\/p>\n<p>    The above story is based on materials provided by    University of Southern    California - Health Sciences. Note: Materials    may be edited for content and length.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>The rest is here:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/www.sciencedaily.com\/releases\/2015\/02\/150219211908.htm\/RK=0\/RS=lGILYTbVaYf6jR6D2RR39_Fbup8-\" title=\"New target for prostate cancer treatment discovered\">New target for prostate cancer treatment discovered<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Keck Medicine of the University of Southern California (USC) scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/genetic-medicine\/new-target-for-prostate-cancer-treatment-discovered.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[5],"tags":[],"class_list":["post-185469","post","type-post","status-publish","format-standard","hentry","category-genetic-medicine"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/185469"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=185469"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/185469\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=185469"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=185469"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=185469"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}